PNT2258: Interim Phase II data

Interim data from 37 patients with relapsed or refractory DLBCL in the open-label, U.S. and Puerto Rican Phase II Wolverine trial showed that once-daily 120 mg/m 2 IV PNT2258 on days 1-5 of each 21-day cycle for 8 induction cycles led to an ORR of 8.1%, a DCR of 18.9% and median PFS of 1.9 months. In 19 patients meeting the amended eligibility criteria of a performance status (PS) score of 0-1, exposure to 1-3 prior systemic regimens and having received >=8 doses of PNT2258 within 35 days of starting therapy, the ORR was 15.8% and the DCR was 36.8%. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...